STOCKHOLM, Sweden, June 23, 2004 (PRIMEZONE) -- Consorta, Inc., a leading health care Group Purchasing Organization, today announced the signing of preferred provider contracts with Elekta both for radiation oncology solutions and for stereotactic radiosurgery solutions.
Elekta was awarded the contract through Consorta's intensive vendor selection process, which focuses on delivering high-quality, cost-effective products and services to Consorta's health care provider customers. Consorta's membership includes more than 400 acute care facilities representing 55,000 beds, and more than 1,700 non-acute care sites.
"Industry leading technology is very important to Consorta members and one of the many reasons we have chosen Elekta as one of our suppliers," said Dan Ingram, manager of imaging contracting for Consorta.
The contract for Elekta's oncology product lines encompasses the company's complete Digital Delivery Systems product line of Linear Accelerators, advanced X-Ray Volume Imaging systems, exclusive Elekta accessories and options, and Radiation Treatment Planning systems. Elekta's most recently announced products for Image-Guided Radiation Therapy (IGRT) are a major part of the agreement.
The contract also covers Elekta's ground breaking IGRT platform, Elekta Synergy(TM) -- the first radiation treatment machine with an integrated imaging system. This technology will enable doctors to obtain images of patients just before their treatment, allowing them to visualize tumors at the point of treatment, to more precisely target tumors with radiation beams. In addition, Consorta members will have access to Elekta Synergy(TM) S (currently a works in progress), the extracranial stereotactic version of Elekta Synergy(TM), featuring a precision Beam Modulator System, which will provide fine resolution beam-shaping.
The contract for Elekta's stereotractic radiosurgery solutions encompasses Leksell Gamma Knife(R), the most proven means of performing intracranial stereotactic radiosurgery, as well as Leksell Stereotactic System(R) and Elekta Neuromag(TM), used worldwide for diagnostic brain mapping.
For further information, please contact:
International: Peter Ejemyr, Group VP Corporate Communications, Elekta AB (publ), Phone: +46 8 587 254 00, e-mail: peter.ejemyr@elekta.com
United States: Lars Jonsteg, VP Investor Relations North America, Elekta, USA Phone: +1 770-670-2419, e-mail: lars.jonsteg@elekta.com
About Consorta:
Consorta, Inc. is a leading health care resource management and group purchasing organization, whose shareholders are faith based or non-profit health systems. As a cooperative, Consorta's shareholders and participants share fully in the organization's bottom-line performance and receive discounts on product purchases through scale purchasing economies. Consorta's shareholders are among the leading integrators of non-profit health care in America, sponsoring significant care providers in many parts of the country. Consorta's shareholder health care systems operate more than half of all Catholic hospitals in the United States, own many extended and alternate care sites and have extensive affiliate relationships with other non-profit hospitals and alternate care facilities.
About Elekta:
Elekta is a world-leading supplier of advanced and innovative radiation oncology and neurosurgery solutions and services for precise treatment of cancer and brain disorders. Elekta's solutions are clinically effective, cost efficient and gentle to the patient.
For additional information about Elekta, please visit www.elekta.com
This information was brought to you by Waymaker http://www.waymaker.net
The following files are available for download:
http://www.waymaker.net/bitonline/2004/06/23/20040623BIT21590/wkr0001.pdf
-0-